Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Share Market News
ASX 200 jumps 1.2%: Big four banks rise, Qantas update, Mesoblast surges
Share Market News
These were last week's best performing ASX shares
Share Market News
ASX 200 Weekly Wrap: Surging commodity prices snap ASX 200's losing streak
Share Gainers
These were the best performing ASX 200 shares last week
Share Market News
Mesoblast's share price gained another 16% in July. Here's why.
Healthcare Shares
Is the Mesoblast share price a sleeping biotech giant?
Share Gainers
Why Mesoblast, Northern Star, PointsBet, & Splitit shares are racing higher
Share Market News
ASX 200 down 1.15%: NAB downgraded, Telstra asset sale, gold miners rocket
Share Market News
These ASX shares are actively fighting coronavirus
How to invest
Here's how to start investing with $5k
Share Market News
Why this broker thinks Mesoblast shares are a strong buy
Share Gainers
Mesoblast share price pushes higher ahead of the "most significant period in its history"
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
